Chronic atrophic gastritis and Helicobacter pylori infection status in liver transplant recipients

Wei Rao,Man Xie,Yun‐jin Zang,Ke‐qian Zhi

DOI: https://doi.org/10.1111/tid.13513

2020-12-09

Transplant Infectious Disease

Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Aim</h3><p>To investigate the abnormalities of the upper gastrointestinal tract in liver transplant (LT) recipients, especially the prevalence of <i>Helicobacter pylori (H. pylori)</i> infection and the incidence of chronic atrophic gastritis (CAG), and to explore the efficacy and safety of <i>H. pylori</i> eradication treatment. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>Endoscopic screening was performed prospectively on LT recipients who received regular follow‐up in our center. A group of healthy subjects with same age and sex was selected as a control group at a ratio of 1:3 with propensity score matching. All <i>H. pylori</i>‐positive recipients received Bismuth‐containing quadruple therapy (esomeprazole 20 mg + clarithromycin 500 mg + amoxicillin 1 g + bismuth 220 mg, all of the medicines were applied twice daily, for 14 days). </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Result</h3><p>The prevalence of <i>H. pylori</i> infection was significantly lower in LT group than control group [12/102(11.8%) vs 98/306(32.0%), P&lt;0.001], whereas the prevalence of CAG was similar between the two groups [48/102 (47.1%)vs 138/306(45.1%), P=0.731]. Meanwhile, the incidence of reflux esophagitis [18/102 (17.6%)vs 31/306(10.1%), P=0.043] and bile regurgitation [19/102(18.6%) vs 30/306(9.8%), P=0.018] were higher in LT group. No correlation between the incidence of upper gastroduodenal abnormalities and postoperative time after liver transplantation was found. The success rate of <i>H. pylori</i> eradication therapy was 100% (10/10). The blood concentration of immunosuppressants was 1.7 to 3.6 times above baseline values during <i>H. pylori</i> eradication therapy, however, no severe adverse effects were observed during the proceed with dose adjustments of the immunosuppressants. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion</h3><p>Although the prevalence of <i>H. pylori</i> infection was lower in LT recipients than in control subjects, the prevalence of CAG was like that of the general population. <i>H. pylori</i> eradication therapy was safe and effective after liver transplantation in our preliminary study. </p></section>

immunology,infectious diseases,transplantation